Drug intelligence / Profile preview

HY19106

Development stage: Preclinical
Lead developer: Suzhou Pharmavan Cancer Research Center
Modality: Small Molecules

Overview

HY19106 is an investigational small molecule drug candidate currently in preclinical development by Suzhou Pharmavan Cancer Research Center. It is being developed for the treatment of cardiovascular diseases, specifically chronic heart failure. As of now, the specific molecular target and mechanism of action for HY19106 have not been publicly disclosed by the developer. The drug represents part of Suzhou Pharmavan's research efforts into innovative therapies for heart failure, a condition characterized by the heart's inability to pump sufficient blood to meet the body's needs.

Beyond the preview

Go deeper on HY19106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY19106.

Explore the full profile